|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.69 USD | +5.62% |
|
+19.52% | -51.44% |
Altamira Therapeutics Ltd. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was CHF 3.87 million compared to CHF 26.53 million a year ago. Basic loss per share from continuing operations was CHF 14.8 compared to CHF 409.6 a year ago.
Basic loss per share was CHF 7.88 compared to CHF 582.58 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -51.44% | 3.79M | |
| -2.60% | 103B | |
| +1.70% | 95.28B | |
| +1.46% | 22.15B | |
| -15.58% | 21.02B | |
| -8.58% | 18.15B | |
| -38.74% | 16.73B | |
| -12.50% | 16.05B | |
| +5.40% | 13.68B | |
| +34.44% | 12.17B |
ALTAMIRA THERAPEUTICS LTD. 
